|
Match
|
Document |
Document Title |
|
|
US20080181885 |
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 202P5A5 USEFUL IN TREATMENT AND DETECTION OF CANCER
A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the...
|
|
|
US20080107627 |
USE OF SARP-1 FOR THE TREATMENT AND/OR PREVENTION OF SCLERODERMA
The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.
|
|
|
US20080107597 |
ISOLATION OF ANTIBODIES THAT CROSS-REACT AND NEUTRALIZE RANKL ORIGINATING FROM MULTIPLE SPECIES
The invention provides specific binding members (e.g., antibodies or antigen-binding fragments thereof) which bind to RANKL originating from multiple species. An epitope recognized by the specific...
|
|
|
US20080102073 |
Antigen-Antibody Complexes as HIV-1 Vaccines
The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and...
|
|
|
US20080095762 |
GLYCOPROTEIN COMPOSITIONS
The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate...
|
|
|
US20080089898 |
Immunotoxins directed against CD33 related surface antigens
The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding...
|
|
|
US20080089897 |
ActRIIB Fusion Polypeptides and Uses Therefor
Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing,...
|
|
|
US20080089837 |
TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to...
|
|
|
US20080085283 |
METHODS FOR THE IDENTIFICATION OF POLYPEPTIDE ANTIGENS ASSOCIATED WITH DISORDERS INVOLVING ABERRANT CELL PROLIFERATION AND COMPOSITIONS USEFUL FOR THE TREATMENT OF SUCH DISORDERS
Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The...
|
|
|
US20080085241 |
Antibody
The present invention provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of tumor specific binding proteins. In particular, the present...
|
|
|
US20080075733 |
Rage Fusion Proteins And Method Of Use
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE...
|
|
|
US20080075722 |
Compostions, kits, and methods for identification, assessment, prevention, and therapy of cancer
The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding...
|
|
|
US20080069823 |
Attenuation of Reperfusion Injury
Compositions for and methods of attenuating and/or preventing ischemia-reperfusion injury (IRI) are provided. One method comprises administering to a patient in need thereof an agent that binds...
|
|
|
US20080069818 |
Method of Increasing Efficacy of Tumor Cell Killing Using Combinations of Anti-Neoplastic Agents
The present invention provides compositions and methods for increasing the amount of active Syk protein kinase in a cell. The compositions and methods are useful for increasing the efficacy of...
|
|
|
US20080063598 |
Humanized Antibody
Novel humanized and chimeric antibodies, humanized antibody fragments, polypeptides sequences of such antibodies and derivatives thereof that specifically bind AF-20 are provided as well as methods...
|
|
|
US20080050379 |
Cancer gene determination and therapeutic screening using signature gene sets
Processes for assaying potential antitumor agents based on their modulation of the expression of specified genes, or sets, of suspected cancer cell genes are disclosed, along with methods for...
|
|
|
US20080050310 |
ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
|
|
|
US20080044429 |
FcγRIIB-Specific Antibodies and Methods of Use Thereof
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind...
|
|
|
US20080044420 |
Anti-IL-13 antibodies, compositions, methods and uses
The present invention relates to at least one novel anti-IL-13 antibody, including isolated nucleic acids that encode at least one anti-IL-13 antibody, IL-13, vectors, host cells, transgenic...
|
|
|
US20080044418 |
Tumor Antigens and Uses Thereof
The invention features tumor antigens; tumor antigen-encoding nucleic acids; antibodies specific for tumor antigens and methods of using the antibodies; methods of identifying tumor antigens and...
|
|
|
US20080044408 |
Cytotoxicity mediation of cells evidencing surface expression of CD63
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease...
|
|
|
US20080038281 |
MODEL MEMBRANE SYSTEMS
The present invention relates generally to modifying biological and/or synthetic membranes or liposomes, or combinations thereof, for the purpose of altering immunity, or for the targeting of drugs...
|
|
|
US20080038280 |
A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
The invention provides a fusion protein, which comprises an antigen binding portion of an A32 human antibody, or variant thereof, and one of the following: (a) an antigen-binding portion of a...
|
|
|
US20080038193 |
Antibodies for use in targeted and temporary treatment of humans and animals
Described is an antibody, or a fragment of an antibody, which binds to an epitope under specifically chosen conditions, and the binding of which to that epitope is broken under specifically chosen...
|
|
|
US20080031887 |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
|
US20080025995 |
Cross-Placenta Delivery System
The invention is directed to chimeral fusion proteins having an IgG1 antibody Fc portion and a lysosomal storage enzyme, particularly a Fc-GUS fusion protein useful in treating Sly's disease in an...
|
|
|
US20080025989 |
ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the...
|
|
|
US20080025977 |
Cytotoxicity mediation of cells evidencing surface expression of CD59
This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and...
|
|
|
US20080019984 |
BLOOD-BRAIN BARRIER TARGETING ANTIBODIES
This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the...
|
|
|
US20080014196 |
COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT
The present invention provides methods of using a DLL4 modulator to modulate vascular development. Furthermore, methods of treatment using DLL4 modulators, such as DLL4 antagonists, are provided.
|
|
|
US20080003230 |
Composition for modulating the expression of cell adhesion molecules
A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a...
|
|
|
US20080003183 |
Nanoparticle radiosensitizers
Herein is described Nanostructure Enhanced X-ray Therapy (NEXT), which uses nanomaterials as radiosensitizers to enhance electromagnetic radiation absorption in specific cells or tissues. The...
|